Prospective longterm minimal residual disease monitoring using RQPCR

  • Slides: 9
Download presentation
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX 1 -RUNX 1 T

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX 1 -RUNX 1 T 1 -positive acute myeloid leukemia: results of the French CBF-2006 trial by Christophe Willekens, Odile Blanchet, Aline Renneville, Pascale Cornillet. Lefebvre, Cécile Pautas, Romain Guieze, Norbert Ifrah, Hervé Dombret, Eric Jourdan, Claude Preudhomme, and Nicolas Boissel haematol Volume 101(3): 328 -335 February 29, 2016 © 2016 by Ferrata Storti Foundation

Patient flow chart. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by

Patient flow chart. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

Peripheral blood (PB) and (BM) bone marrow MRD in 525 paired samples. Christophe Willekens

Peripheral blood (PB) and (BM) bone marrow MRD in 525 paired samples. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

Correlation between paired BM and PB MRD transcript ratio at specific time-points. Christophe Willekens

Correlation between paired BM and PB MRD transcript ratio at specific time-points. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

Characteristics of the 94 patients with CBFA-AML included in the CBF-2006 trial. Christophe Willekens

Characteristics of the 94 patients with CBFA-AML included in the CBF-2006 trial. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

Outcome according to PB- or BM-MRD at the end of consolidation therapy (MRD 4).

Outcome according to PB- or BM-MRD at the end of consolidation therapy (MRD 4). Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

PB- and BM-MRD in 8 patients with persistent BM-MRD up to two years after

PB- and BM-MRD in 8 patients with persistent BM-MRD up to two years after end of treatment. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

Impact of CMR achievement on patient outcome. Christophe Willekens et al. Haematologica 2016; 101:

Impact of CMR achievement on patient outcome. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

Impact of molecular relapse in patients with complete molecular remission. Christophe Willekens et al.

Impact of molecular relapse in patients with complete molecular remission. Christophe Willekens et al. Haematologica 2016; 101: 328335 © 2016 by Ferrata Storti Foundation

Prospective longterm minimal residual disease monitoring using RQPCRProspective longterm minimal residual disease monitoring using RQPCR
Residual Income Valuation What is residual income ResidualResidual Income Valuation What is residual income Residual
Residual Income Valuation What is residual income ResidualResidual Income Valuation What is residual income Residual
residual stresses residual stresses analysis of residual stressesresidual stresses residual stresses analysis of residual stresses
Minimal Residual Disease Negativity Does Not Overcome PoorMinimal Residual Disease Negativity Does Not Overcome Poor
Peripheral Immunotype Correlates with Minimal Residual Disease StatusPeripheral Immunotype Correlates with Minimal Residual Disease Status
Minimal Residual Disease Testing Dr Christopher Venner CrossMinimal Residual Disease Testing Dr Christopher Venner Cross
Minimal Residual Disease and Biomarkers ASH 2015 SummaryMinimal Residual Disease and Biomarkers ASH 2015 Summary